{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T22:06:39Z","timestamp":1769292399195,"version":"3.49.0"},"reference-count":41,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union NextGenerationEU procedure \u201cCreating a network of research universities\u201d from the National Plan for Recovery and Resilience, project \u201cResearch University, Medical University, Pleven\u201d","award":["#BG-RRP-2.004-0003-C01"],"award-info":[{"award-number":["#BG-RRP-2.004-0003-C01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiologia"],"abstract":"<jats:p>Background\/Objectives: Prostate cancer is the second most common cause of cancer-related mortality among the male population worldwide. It is among the leading reasons for the increasing number of years of life lost, working years of life lost, and gross domestic product (GDP) loss in Bulgaria. The primary objective of this study is to evaluate the burden of prostate cancer in Bulgaria, including calculating years of life lost (YLL), years of working life lost (YWLL), and the associated indirect costs. Methods: An observational time-series study was conducted using official national data from the National Statistical Institute (NSI), the INFOSTAT database, and the National Social Security Institute. The study covered the period 2008\u20132023 and included all registered male deaths attributed to malignant neoplasm of the prostate (ICD-10: C61). YLL, YWLL, and indirect costs were calculated using the human capital approach. Due to restricted access to age-specific mortality files, additional mortality records were obtained through formal data requests to NSI. Results: Prostate cancer led to 127,457 YLL and 6345 YWLL, with productivity losses reaching \u20ac88.2 million. Mortality showed an overall increasing trend up to 2020, while YWLL declined due to deaths shifting to older age groups. Conclusions: Despite the advancements in prostate cancer diagnosis and treatment, our findings demonstrate a negative trend regarding YLL, YWLL, and indirect costs associated with the disease, in contrast to other European countries. Strengthening early screening, reducing diagnostic delays, and improving national cancer registry capacity are critical to mitigating future health and economic losses.<\/jats:p>","DOI":"10.3390\/epidemiologia7010016","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:41:34Z","timestamp":1769164894000},"page":"16","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mortality and Economic Burden of Prostate Cancer in Bulgaria: Years of Life Lost, Working Years of Life Lost, and Indirect Costs (2008\u20132023)"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1027-5951","authenticated-orcid":false,"given":"Nadia","family":"Veleva","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University\u2014Pleven, 5800 Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University\u2014Pleven, 5800 Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Yaneva","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University\u2014Pleven, 5800 Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-6965","authenticated-orcid":false,"given":"Hristina","family":"Lebanova","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University\u2014Pleven, 5800 Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European Cancer Burden in 2020: Incidence and Mortality Estimates for 40 Countries and 25 Major Cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., and Du, L. (2022). Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.811044"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","article-title":"The Global Burden of Cancer Attributable to Risk Factors, 2010\u20132019: A Systematic Analysis for the Global Burden of Disease Study 2019","volume":"400","author":"Tran","year":"2022","journal-title":"Lancet"},{"key":"ref_5","first-page":"30","article-title":"Correlation Analysis of Prostate Cancer Incidence and Mortality Worldwide, in Europe and in Bulgaria","volume":"25","author":"Kalchev","year":"2020","journal-title":"J. Union. Sci.-Varna Med. Ecol. Ser."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and Prevention of Prostate Cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/pros.24360","article-title":"Current and Projected Number of Years of Life Lost Due to Prostate Cancer\u2014A Global Study","volume":"82","author":"Withrow","year":"2022","journal-title":"Prostate"},{"key":"ref_8","unstructured":"ECIS (2024, September 08). European Cancer Information System Data Explorer. Available online: https:\/\/ecis.jrc.ec.europa.eu\/explorer.php?$0-0$1-BG$2-All$4-1$3-All$6-0,85$5-2022,2022$7-7$CEstByCancer$X0_8-3$CEstRelativeCanc$X1_8-3$X1_9-AE27$CEstBySexByCancer$X2_8-3$X2_-1-1."},{"key":"ref_9","unstructured":"(2025, August 25). Bulgarian National Cancer Control Plan 2027, Available online: https:\/\/www.mh.government.bg\/bg\/strategii\/nacionalni-planove."},{"key":"ref_10","unstructured":"OECD (2023). Bulgaria: Country Health Profile 2023, OECD. Available online: https:\/\/www.oecd.org\/en\/publications\/bulgaria-country-health-profile-2023_8d90f882-en.html."},{"key":"ref_11","unstructured":"WHO (2023). Bulgaria: Prostate Cancer Mortality Statistics, WHO. Available online: https:\/\/data.who.int\/countries\/100."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjc.6602321","article-title":"Years of Life Lost (YLL) from Cancer Is an Important Measure of Population Burden\u2014And Should Be Considered When Allocating Research Funds","volume":"92","author":"Burnet","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/bjc.2014.364","article-title":"Years of Life Lost as a Measure of Cancer Burden on a National Level","volume":"111","author":"Brustugun","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ijc.33826","article-title":"Paid and Unpaid Productivity Losses Due to Premature Mortality from Cancer in Europe in 2018","volume":"150","author":"Hanly","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s13167-019-00169-y","article-title":"The Burden of Prostate Cancer Is Associated with Human Development Index: Evidence from 87 Countries, 1990\u20132016","volume":"10","author":"Sharma","year":"2019","journal-title":"EPMA J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 Cancer Estimates: Data Sources, Methods, and a Snapshot of the Cancer Burden Worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and Mortality Rates and Trends\u2014An Update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_18","unstructured":"(2025, June 25). National Statistical Institute Tables for the Conditions for Acquiring the Right to a Pension for Insurance Years and Age. Available online: https:\/\/www.noi.bg\/wp-content\/uploads\/table1_2019.pdf."},{"key":"ref_19","unstructured":"(2025, August 21). National Statistical Institute Information System INFOSTAT of the National Statistical Institute. Available online: https:\/\/infostat.nsi.bg\/infostat\/pages\/reports\/result.jsf?x_2=185."},{"key":"ref_20","unstructured":"(2025, June 21). IBM SPSS. Available online: https:\/\/www.ibm.com\/products\/spss."},{"key":"ref_21","unstructured":"(2025, August 21). OECD\/European Observatory on Health Systems and Policies Bulgaria: Country Cancer Profile 2023. Available online: https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2023\/02\/eu-country-cancer-profile-bulgaria-2023_c9a57aa0\/f6915046-en.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1470-2045(20)30265-5","article-title":"Fewer Cancer Diagnoses during the COVID-19 Epidemic in the Netherlands","volume":"21","author":"Dinmohamed","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/CCI.20.00068","article-title":"Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters","volume":"4","author":"London","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41416-024-02931-0","article-title":"The Long-Lasting Impacts of the COVID-19 Pandemic on Population-Based Cancer Survival: What Are the Implications for Data Analysis?","volume":"132","author":"Stannard","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_26","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-Free Survival and Radiotherapy in Patients with Newly Diagnosed Nonmetastatic Prostate Cancer: Data from Patients in the Control Arm of the STAMPEDE Trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Men with Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2021.39.15_suppl.5000","article-title":"A Phase 3 Trial with a 2 \u00d7 2 Factorial Design of Abiraterone Acetate plus Prednisone and\/or Local Radiotherapy in Men with de Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC): First Results of PEACE-1","volume":"39","author":"Fizazi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide Treatment and Metastasis-Free Survival in Prostate Cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","unstructured":"EFPIA (2025, August 25). The Root Cause of Unavailability and Delay to Innovative Medicines: Reducing the Time before Patients Have Access to Innovative Medicines. Available online: https:\/\/www.efpia.eu\/media\/636822\/root-cause-unavailability-delays-cra-report-april-2022-final.pdf."},{"key":"ref_38","unstructured":"Newton, M., Stoddart, K., Travaglio, M., and Troein, P. (2025, August 25). EFPIA Patients W.A.I.T. Indicator 2024 Survey. Available online: https:\/\/www.efpia.eu\/media\/oeganukm\/efpia-patients-wait-indicator-2024-final-110425.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.clinthera.2023.08.006","article-title":"Dynamic Regulatory Assessment: Unpacking the Process Reveals Readiness to Pilot for Europe-An EFPIA View","volume":"45","author":"Todd","year":"2023","journal-title":"Clin. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14748\/ahp.v11i1.10413","article-title":"Access to Targeted Therapy for Prostate Cancer in Bulgaria","volume":"11","author":"Ivanov","year":"2025","journal-title":"Annu. Hosp. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/03075079.2017.1359823","article-title":"Limitations of Human Capital Theory","volume":"44","author":"Marginson","year":"2019","journal-title":"Stud. High. Educ."}],"container-title":["Epidemiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-3986\/7\/1\/16\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:17:54Z","timestamp":1769167074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-3986\/7\/1\/16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["epidemiologia7010016"],"URL":"https:\/\/doi.org\/10.3390\/epidemiologia7010016","relation":{},"ISSN":["2673-3986"],"issn-type":[{"value":"2673-3986","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}